Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. BinJ/VIF-prME chimeric viruses.
  • Fig. S2. Inoculation of immunodeficient mice with high titers of BinJ/ZIKV-prME virus.
  • Fig. S3. Cryo-EM 3D reconstructions and data for BinJ/ZIKV-prME chimeras.
  • Fig. S4. BinJ/ZIKV-prME vaccination of female IFNAR−/− mice.
  • Fig. S5. BinJ/ZIKV-prME formulated with and without AddaVax (male mice).
  • Fig. S6. BinJ/ZIKV-prME formulated with and without AddaVax (female mice).
  • Table S1. Summary of flaviviruses of medical importance and their respective vaccine status for flaviviruses used in this study.
  • Table S2. Source of flavivirus sequences used in Fig. 1A.
  • Table S3. Summary of deep sequencing analyses of indicated chimeric viruses.
  • Table S4. Previously described and new mAbs used in this study.
  • Table S5. Refinement statistic details for mature, immature, and C8-complexed BinJ/ZIKV-prME virions to accompany the data in Fig. 3 and fig. S3.
  • Table S6. Kd values for binding of mAbs to the indicated BinJ/VIF-prME and corresponding VIFs.
  • Table S7. Examples of detection assays used for diagnostics of flavivirus infection.
  • Table S8. Examples of inactivated and VLP-based flavivirus vaccines.
  • References (65145)

[Download PDF]

Other Supplementary Material for this manuscript includes the following: